Clinical Trial Update: Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update examining temozolomide with or without veliparib in relapsed or refractory small cell lung cancer, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Temodar (Temozolomide)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Lung Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-03-27